THE EFFECT OF INCREASED ADHERENCE TO GLYCEMIC CONTROL ON CORONARY HEART DISEASE AND QUALITY OF LIFE IN PATIENTS WITH
Ya Dzhun1, G Mankovsky1, N Rudenko2
11Government Institution «The Scientific and Practical Medical Center of Pediatric Cardiology and Cardiac Surgery of the Ministry of Health of Ukraine», Kyiv; Ukraine.
Insights
Continuous glucose monitoring (CGM) significantly improved quality of life and physical activity in patients with type 2 diabetes and ischemic heart disease. CGM use led to better glycemic control and increased patient satisfaction.
Area of Science:
- Cardiology
- Endocrinology
- Quality of Life Research
Background:
- Ischemic heart disease (IHD) and type 2 diabetes mellitus (T2DM) often coexist, significantly impacting patient quality of life.
- Effective glycemic control is crucial for managing T2DM and mitigating cardiovascular complications.
Purpose of the Study:
- To evaluate the impact of continuous glucose monitoring (CGM) versus self-blood glucose monitoring (SBGM) on quality of life and IHD course in T2DM patients.
- To assess changes in glycemic control, physical activity, and overall well-being.
Main Methods:
- A 3-month study involving 44 T2DM patients with IHD, randomized into CGM (n=21) and SBGM (n=23) groups.
- Data collection included HbA1c, blood glucose levels, arterial pressure, pulse, physical exertion duration, and SF-36 quality of life questionnaires.
Main Results:
- CGM group showed a statistically significant decrease in HbA1c and increase in physical activity compared to SBGM.
- CGM use was associated with improved physical functioning, reduced pain, and enhanced general health scores (SF-36).
- Patients using CGM reported higher satisfaction levels and improved social functioning.
Conclusions:
- Continuous glucose monitoring is a valuable tool for improving quality of life in T2DM patients with IHD.
- CGM facilitates better glycemic control, increased physical activity, and enhanced overall well-being, leading to higher patient satisfaction.
Abstract:
Aim of the study - to evaluate the impact of increased adherence to glycemic control on the improvement of quality of life and the course of ischemic heart disease (IHD) in patients with diabetes. The study includes 44 patients (26 males -59%, 18 females - 41%), diagnosed with IHD (functional class І-ІІІ of exertion angina) and accompanying type 2 DM. Depending on the glycaemia control method, the patients were divided in two groups. In group I (CGM, n=21) the glycaemia control was based on CGM, when in group II (self-blood glucose monitoring - SBGM, n=23) it was based on individual glucose level self-measurement, performed 4 times per day. Distribution of patients between groups I and II by gender, age, anthropometric characteristics, DM duration, functional heart and kidney condition, acute cardio-vascular events in anamnesis and harmful habits (smoking) is without significant differences. Besides glycaemia monitoring, the patients recorded their arterial pressure, pulse and duration of their physical exertions (minutes a day). During patients' elective visits (0-3 months) glycated hemoglobin was measured in both patient groups, and they filled in the life quality questionnaire. The use of CGM for monitoring glycaemia level in patients with IHD and type II DM during 3 months has been associated with statistically significant decrease of glycated hemoglobin level, increase of physical activity. Also CGM improved physical condition and life quality according to the physical health scores SF-36 (physical function, physical function role, physical pain, general health) and social function scores, with reliable increase in group I compared to group II. There are no differences in body weight decrease or improved carbohydrate metabolic data have been detected. Administration of the CGM in patients with IHD is associated with improved quality of life and higher satisfaction level, decreased fasting HbA1c and glucose, and also increasing level of physical exertion level.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:15Diabetes: Symptoms, Diagnosis, and Complications
01:22Diabetes Mellitus: Type 2 and Gestational
01:26Coronary Artery Disease IV: Preventive Measures
01:22Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:26Atherosclerosis III: Management